Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

NCT04820023 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
45
Enrollment
INDUSTRY
Sponsor class

Stopped Sponsor's decision considering the changing treatment landscape for NSCLC

Conditions

Interventions

Sponsor

Bridge Biotherapeutics, Inc.